JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB185213

Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal

Be the first to review this product! Submit a review

|

(2 Publications)

Rabbit Recombinant Monoclonal CP2CJ antibody. C-terminal. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 2 publications.

View Alternative Names

Cytochrome P450 2C19, (R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CYPIIC17, CYPIIC19, Cytochrome P450-11A, Cytochrome P450-254C, Fenbendazole monooxygenase (4'-hydroxylating), Mephenytoin 4-hydroxylase, CYP2C19

5 Images
Immunocytochemistry/ Immunofluorescence - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)

Immunofluorescent analysis of 4% paraformaldehyde fixed 293 cells labeling Cytochrome P450 2C19 with ab185213 at 1/250 followed by Goat anti rabbit IgG (Alexa Fluor®555) at 1/200 and counterstained with Dapi.

Flow Cytometry (Intracellular) - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)
  • Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)

Intracellular flow cytometric analysis of2% paraformaldehyde fixed HeLa cells labeling Cytochrome P450 2C19 with ab185213 at 1/240 (red) or Rabbit monoclonal IgG (green)followed byGoat anti rabbit IgG (FITC) at 1/150.

Immunoprecipitation - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)
  • IP

Supplier Data

Immunoprecipitation - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)

Immunoprecipitation analysis of 293 cell lysate immunoprecipitated for Cytochrome P450 2C19 using ab185213 at 1/50 dilution (Lane 1). A aAnti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1500 dilution was used as secondary. Lane 2 : PBS instead of 293 lysates

All lanes:

Immunoprecipitation - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (ab185213)

Predicted band size: 56 kDa

Observed band size: 52 kDa

false

Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)
  • WB

Supplier Data

Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)

All lanes:

Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (ab185213) at 1/5000 dilution

Lane 1:

HeLa cell lysate at 10 µg

Lane 2:

293 cell lysate at 10 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated antibody at 1/1000 dilution

Predicted band size: 56 kDa

Observed band size: 52 kDa

false

Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)
  • WB

Supplier Data

Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (AB185213)

All lanes:

Western blot - Anti-Cytochrome p450 2C19 antibody [EPR6577] - C-terminal (ab185213) at 1/1000 dilution

All lanes:

Human fetal liver lysate at 10 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 56 kDa

Observed band size: 52 kDa

false

  • Carrier free

    Anti-Cytochrome p450 2C19 antibody [EPR6577] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR6577

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

ICC/IF, Flow Cyt (Intra), WB, IP

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/40 - 1/60", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/250", "ICCIF-species-notes": "<p></p>", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/240", "FlowCytIntra-species-notes": "<p><a href='/en-us/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.</p>" } } }
style
left-column

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cytochrome p450 2C19 also known as CYP2C19 is a member of the cytochrome P450 superfamily of enzymes. It acts as a monooxygenase which means it catalyzes oxidation reactions in several substrates. The enzyme is approximately 55 kDa in mass and is mainly expressed in the liver. However it is also found in other tissues such as the intestines and brain. CYP2C19 plays a role in drug metabolism breaking down various endogenous and xenobiotic compounds.
Biological function summary

Cytochrome p450 2C19 contributes to the body's drug metabolism and detoxification processes. It is not part of any known enzymatic complex but plays a direct role in the metabolism of many clinically relevant drugs including proton pump inhibitors and antiplatelet medications. Through these actions the enzyme protects the body from potentially harmful effects of drugs and helps maintain metabolic homeostasis. This enzyme has genetic polymorphisms that lead to differences in drug metabolism among different individuals.

Pathways

The enzyme plays a significant role in the drug metabolism and pharmacokinetics pathways. CYP2C19 is involved in the hepatic phase I drug metabolism pathway where it metabolizes drugs into more polar excretable forms. It relates to other enzymes like CYP2C9 and CYP2D6 which together with it form the main subfamilies involved in the oxidation of a diverse range of lipophilic drugs and compounds. This allows for the extensive breakdown and unloading of various substances utilized in therapeutic contexts.

Cytochrome p450 2C19 variations can influence the metabolism of medications used in the treatment of cardiovascular diseases and depression. For example CYP2C19 polymorphisms affect the activation of the antiplatelet drug clopidogrel impacting patient outcomes in cardiovascular therapies. Additionally in psychiatric disorders variations in CYP2C19 can alter the effectiveness of selective serotonin reuptake inhibitors (SSRIs) which rely on the enzyme for their metabolism. It also links to CYP2C19's relationship with the CYP2C9 and CYP2D6 enzymes which share impact in drug efficacy and safety in different therapeutic areas.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) (PubMed : 18577768, PubMed : 19965576, PubMed : 20972997). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed : 18577768, PubMed : 19965576, PubMed : 20972997). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates PUFA specifically at the omega-1 position (PubMed : 18577768). Catalyzes the epoxidation of double bonds of PUFA (PubMed : 19965576, PubMed : 20972997). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed : 11950794). Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Hydroxylates fenbendazole at the 4' position (PubMed : 23959307).
See full target information CYP2C19
style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 14:1157421 PubMed36960056

2023

Degradation of collagen I by activated C1s in periodontal Ehlers-Danlos Syndrome.

Applications

Unspecified application

Species

Unspecified reactive species

Albert Amberger,Johanna Pertoll,Pia Traunfellner,Ines Kapferer-Seebacher,Heribert Stoiber,Lars Klimaschewski,Nicole Thielens,Christine Gaboriaud,Johannes Zschocke

Drug metabolism and disposition: the biological fate of chemicals 49:361-368 PubMed33674270

2021

The Long Noncoding RNA Hepatocyte Nuclear Factor 4 Antisense RNA 1 Negatively Regulates Cytochrome P450 Enzymes in Huh7 Cells via Histone Modifications.

Applications

Unspecified application

Species

Unspecified reactive species

Pei Wang,Shitong Chen,Yiting Wang,Xiaofei Wang,Liang Yan,Kun Yang,Xiao-Bo Zhong,Shengna Han,Lirong Zhang
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB124921

Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome P450 3A4/CYP3A4 antibody [EPR6202] (AB124921)

  • 4
  • 1
Primary Antibodies

AB150364

Anti-CYP2C9 antibody [EPR7340]

RabMAb|Recombinant

Western blot - Anti-CYP2C9 antibody [EPR7340] (AB150364)

  • 0
  • 0
Primary Antibodies

AB151728

Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-Cytochrome P450 1A2 antibody [EPR6138(2)] (AB151728)

  • 0
  • 0
Primary Antibodies

AB185625

Anti-CYP2D6 antibody [EPR17868]

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP2D6 antibody [EPR17868] (AB185625)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com